diabetestalk.net

Fiasp, A New, Ultra-fast Acting Mealtime Insulin Is Available For The Treatment Of Diabetes In Adults

Fiasp, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults

Fiasp, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults


Fiasp, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults
Bagsvrd, Denmark (ots/PRNewswire) - Canada first country to launch Fiasp
This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
Today, Novo Nordisk announced that Fiasp, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
Fiasp is insulin aspart in an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes after a meal, compared with NovoRapid (conventional insulin aspart)[1]. Fiasp also has the option of a flexible dosing regimen (up to 20 minutes after starting a meal), without compromising overall glycaemic control, when compared to NovoRapid dosed at mealtime [2],[3].
"The launch of Fiasp in Canada represents the first new mealtime insulin in 10 years. We hope to make this innovation available to as many people with diabetes as possible worldwide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The goal of any insulin treatment is to match the natural physiological insulin production we see in people without diabetes, both in speed and glycaemic control. Fiasp has narrowed the existing gap, getting us closer to that goal."
Fiasp is absorbed faster than NovoRapid, appearing twice as fast in the bloodstream after injection[1],[3], which leads to imp Continue reading

Rate this article
Total 1 ratings
Drinking Red Wine With Type 2 Diabetes: Resveratrol Benefits Heart Health By Reducing Arterial Stiffness

Drinking Red Wine With Type 2 Diabetes: Resveratrol Benefits Heart Health By Reducing Arterial Stiffness


Drinking Red Wine With Type 2 Diabetes: Resveratrol Benefits Heart Health By Reducing Arterial Stiffness
In the battle of the wines, when it comes red versus white, science tends to side with the darker blend. Drinking red wine has been touted for its health benefits, especially for diabetics, from improving cholesterol to blood sugar levels. Now, researchers at Boston University in Massachusetts suggest there's another reason to toast it can decrease artery stiffness in people with type 2 diabetes.
Resveratrol, an antioxidant commonly present in some wine and fruits, is found to have a protective effect against heart disease by improving vascular function and reducing inflammation. The natural compound is known to slow down premature aging of the arteries by activating SIRT1 a gene that slows down the aging. Specifically, it's able to reduce the stiffness of the aorta, which is the main artery that transports blood from the heart and into the rest of the body.
Read More: People With Type 2 Diabetes May Benefit From Drinking Red Wine In The Context Of A Healthy, Mediterranean Diet
In the new study , presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology and Peripheral Vascular Disease 2017 Scientific Sessions in Minnesota, researchers found a 300 milligram (mg) per day dose of resveratrol decreased aortic stiffness by 9 percent in type 2 diabetes patients. Resveratrol's effect was also seen with a 100 mg daily intake of resveratrol, whichreduced aortic stiffness by 4.8 percent. Contrastingly, patients given the placebo treatm Continue reading

Succeeding with Diabetes on a Vegan Diet

Succeeding with Diabetes on a Vegan Diet


Lee Ann Thill was diagnosed with type 1 diabetes at the age of 5, back in 1978. I had just started kindergarten, and had all the classic symptoms peeing a lot, drinking a lot, weight loss. My mom took me to the pediatrician after she realized there was something wrong, and I was diagnosed. We went straight to the hospital, where I stayed for two weeks.
Like many of us who were diagnosed decades ago, the narratives around food were confusing. From sweets restrictions to the exchange diet, there wasnt a set diabetes diet that people followed. I dont remember following a diet, aside from avoiding sweets. My mom had an interest in healthful eating and fitness, so the way we ate at home reflected the dieting trends of the times, which amounted to less refined grains, and lower fat foods. I was still allowed to have sweets on special occasions, but we typically didnt have foods like that in the house.
Today, 40 years later, Lee Ann has moved to a vegan diet and lifestyle to manage both her diabetes and her desire to affect positive social change. At age 14, I developed an eating disorder, and didnt recover until age 32, she said. Becoming vegan has reinforced my healing process. For some people, it might appear that Ive traded one category of forbidden foods for another, but as a vegan, I dont think of, lets say, a cheeseburger, as food. Plus, I eat vegan cheeseburgers, so its not like Im missing out. An important idea that has emerged for me from my eating disorder recovery is that everyone including animals deserves to be respected for exactly who they are, nourished, a Continue reading

The effect of high-intensity breastfeeding on postpartum glucose tolerance in women with recent gestational diabetes

The effect of high-intensity breastfeeding on postpartum glucose tolerance in women with recent gestational diabetes


The effect of high-intensity breastfeeding on postpartum glucose tolerance in women with recent gestational diabetes
Although breastfeeding is expected to reduce the incidence of diabetes in women with gestational diabetes, the effect has not been clearly confirmed. We examined whether or not high-intensity breastfeeding reduces the incidence of abnormal glucose tolerance and investigated the effect of high-intensity breastfeeding on insulin resistance during the first year postpartum in Japanese women with current gestational diabetes.
In this retrospective study, we included women with gestational diabetes who underwent postpartum 75g oral glucose tolerance test during the first year (12-14months) postpartum from 2009 to 2011 at a single tertiary perinatal care center in Japan. High-intensity breastfeeding was defined as the condition in which infants were fed by breastfeeding alone or 80% or more of the volume. We investigated the effect of high-intensity breastfeeding on the prevalence of postpartum abnormal glucose tolerance and the postpartum homeostasis model of assessment of insulin resistance (HOMA-IR), after controlling for confounders, including prepregnancy obesity and weight changes during pregnancy and postpartum.
Among 88 women with gestational diabetes, 46 (52%) had abnormal glucose tolerance during the postpartum period. High-intensity breastfeeding women (n = 70) were significantly less likely to have abnormal glucose tolerance than non-high-intensity breastfeeding women (n = 18) (46% vs. 78%, p = 0.015). High-intensity breastfeeding was also associat Continue reading

Broccoli extract may lower blood sugar among some with diabetes, study finds

Broccoli extract may lower blood sugar among some with diabetes, study finds


Nearly 30 million people in the United States have type 2 diabetes. Being overweight or obese increases the chances of developing diabetes. Both obesity and diabetes are linked to cancer .
Findings from a new study published in the journal Science Translational Medicine suggest that sulforaphane, a phytochemical that has shown strong cancer-preventive actions in lab and clinical studies, might also reduce some of the harmful effects of type 2 diabetes in obese adults.
Sulforaphane is useful not only for cancer prevention but it also demonstrates anti-diabetes and many other activities, says Jed Fahey, ScD, Director of the Cullman Chemoprotection Center at the Johns Hopkins School of Medicine and one of the authors on the study.
Sulforaphane comes from broccoli and other cruciferous vegetables such as kale, cabbage, and radishes. It contributes to the vegetables slightly pungent aroma and flavor.
Both obesity and diabetes increase the risk of cancers. Read more in Linking Diabetes to Cancer: Changes for Prevention.
The liver of a healthy person naturally produces glucose, a type of sugar, and releases it into the blood. But the liver of a person with poorly controlled type 2 diabetes produces as much as three times the normal amount of glucose.
A team of scientists from Sweden, Switzerland, and the U.S. set out to learn what effects sulforaphane has on liver glucose production and blood sugar control in people with type 2 diabetes. They chose sulforaphane out of more than 3,800 drugs and natural products because the pattern of genes that sulforaphane switches on or o Continue reading

No more pages to load

Popular Articles

Related Articles

  • New Insulin Fiasp

    Faster Insulin: The Holy Grail of Type-1 Diabetes OK, my kids are right. I’m a geek. Monty Python movies still crack m...

    insulin May 30, 2018
  • Fiasp Insulin

    Novo Nordisk’s Fiasp (insulin aspart) 100 Units/mL has been approved by the US FDA. Fiasp is a fast-acting mealtime in...

    insulin Jun 30, 2018
  • Fiasp Insulin Pump

    You may have heard that Fiasp is Novo Nordisks new meal-time (bolus) insulin and was recently released in U.S. pharmaci...

    insulin May 29, 2018
  • Fiasp Vs Novolog

    Fiasp, a new, faster-acting insulin from Novo Nordisk, is generating a lot of interest and carries with it much potentia...

    insulin Jun 12, 2018
  • Mealtime Insulin Brands

    Indication BASAGLAR is a long-acting insulin used to control high blood sugar in adults and children with type 1 diabete...

    insulin Apr 30, 2018
  • What Is A Mealtime Insulin?

    Step 1: Is the Goal Appropriate for the Patient? If your patient continues to have trouble controlling their blood sugar...

    insulin Dec 23, 2020
  • Mealtime Insulin Types

    insulin glulisine [rDNA origin] injection Apidra insulin glulisine [rDNA origin] injection $10* COPAY FOR LANTUS FOR 12...

    insulin Apr 30, 2018
  • Mealtime Insulin Dose Calculator

    Go to: Abstract Medical apps are widely available, increasingly used by patients and clinicians, and are being actively ...

    insulin May 4, 2018
  • Mealtime Insulin Dosing

    Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes...

    insulin May 4, 2018